Identification of Kallikrein and FXIa as impurities in therapeutic immunoglobulins: Implications for the safety and control of intravenous blood products

Vox Sanguinis

Volumn 102, Issue 1, 2012, Pages 40-46

  Etscheid, M ^a   Breitner Ruddock, S ^a   Gross, S ^a   Hunfeld, A ^a   Seitz, R ^a   Dodt, J ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

FXI; FXIa; Intravenous immunoglobulin; Plasma kallikrein; Prekallikrein activator; Thromboembolic events

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 11A; DEXTRO ISOLEUCYLPROLYLARGININE 4 NITROANILIDE; DEXTRO PROLYLPHENYLALANYLARGININE 4 NITROANILIDE; HEMOSTATIC AGENT; IMMUNOGLOBULIN; KALLIKREIN; PLASMA PROTEIN; PLASMIN; PREKALLIKREIN; PROTEINASE; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG IMPURITY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FIBRINOLYSIS; HUMAN; IC 50; IMMUNOASSAY; IMMUNOCAPTURE ASSAY; NON ACTIVATED PARTIAL THROMBOPLASTIN TIME; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; THROMBOEMBOLISM; THROMBOPLASTIN TIME;

BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CONTAMINATION; DRUG TOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIA; FACTOR XIIA; FIBRINOLYSIN; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; KALLIKREINS; PARTIAL THROMBOPLASTIN TIME; PREKALLIKREIN; THROMBIN; THROMBOEMBOLISM;

EID: 84655167911     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01502.x     Document Type: Article

References (20)

1. Marie I, Maurey G, Herve F, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006; 155:714-721.
2. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16:313-318.
3. Luben G, Quast U, Geiger H: Prekallikrein activator levels and side effects with human albumin preparations. Dev Biol Stand 1980; 48:123-127.
4. Alving BM, Tankersley DL, Mason BL, et al. Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96:334-346.
5. Heinonen J, Peltola K, Himberg JJ, et al. Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: a clinical study in patients having open-heart surgery. Ann Thorac Surg 1982; 33:244-249.
6. Van Rosevelt RF, Bakker JC, Sinclair DM, et al. Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J Lab Clin Med 1982; 100:288-295.
7. Kaplan AP, Austen KF: A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971; 133:696-712.
8. Revak SD, Cochrane CG, Johnston AR, et al. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54:619-627.
9. Cochrane CG, Griffin JH: Molecular assembly in the contact phase of the Hageman factor system. Am J Med 1979; 67:657-664.
10. Kaplan AP, Austen KF: A pre-albumin activator of prekallikrein. J Immunol 1970; 105:802-811.
11. The European Pharmacopoeia: The Directorate for the Quality of Medicines and Healthcare of the Council of Europe, 7th edn. Strasbourg, France, 2011.
12. Hunfeld A, Etscheid M, König H, et al. Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors. FEBS Lett 1999; 456:290-294.
13. Lehmann EL, D'Abrera HJM (eds): Nonparametrics: Statistical Methods Based on Ranks. New York, Springer, 2006.
14. Etscheid M, Beer N, Fink E, et al. The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin. Biol Chem 2002; 383:1633-1643.
15. Römisch J: Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002; 383:1119-1124.
16. Wolberg AS, Kon RH, Monroe DM, et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65:30-34.
17. Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I: the characterisation of the protein fractions of human plasma. J Clin Invest 1944; 23:417-432.
18. Kistler P, Nitschmann H: Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7:414-424.
19. Griffin JH: Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci U S A 1978; 75:1998-2002.
20. Grundmann C, Kusch M, Keitel S, et al. Modified thrombin generation assay: application to the analysis of immunoglobulin concentrates. WebmedCentral IMMUNOTHERAPY 2010; 1:1-13.